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West Nile Virus (WNV) is an RNA arbovirus in the family Flaviviridae.  
While birds are the primary reservoir for the virus, humans can be a dead 
end host.  In Wyoming, the Culex tarsalis mosquito acts as the primary 
vector.  Most human infections are asymptomatic.  In less than 1% of in-
fections, however, severe symptoms including paralysis, menengitis, en-
cephalitis, and death may occur.  Fremont County is a hot spot of WNV 
with 64% of all cases in Wyoming reported in 2007.  Our study proposes 
the testing of a percentage of the human population of Fremont County to 
determine the number of people exposed to WNV.  Sera will be tested us-
ing commercially available IgG and IgM antibody kits.  
Introduction 
West Nile Virus (WNV) was originally discovered in Uganda in 1937. 
WNV is a flavivirus, the same genus of viruses as Dengue Fever, Tick 
Borne Encephalitis, and Yellow Fever.  WNV is a (+) RNA virus that en-
ters a cell, mimics the host cell’s mRNA, and replicates. The primary 
vector of WNV to humans is the mosquito, specifically Culex tarsalis.  
Individuals who contract the disease may experience no symptoms, mild 
symptoms of fever and malaise, or severe disabling illness (including en-
cephalitis, meningitis, and polio-like paralysis).  Severe illness is present 
in < 1.0% of those affected by the virus. There is no vaccine for WNV 
available in the United States. 
 
WNV was first detected in the United States in 1999.  The virus rapidly 
migrated across the lower-48 continental states over the course of ten 
years.  Human and equine cases of WNV were first discovered in Wyo-
ming in 2002, with 2 human cases.  2007 was the height of the preva-
lence of WNV caused illness in Wyoming.  185 humans were diagnosed 
with WNV, including two fatalities, during that year.  Since 2007, the 
rate of human cases has precipitously dropped.  In 2009 there were 12 
diagnosed human cases, with one fatality in Wyoming. 
 
In 2007 the majority of the human cases occurred in Fremont County – 
118 cases including one fatality.  Fremont County had 4 cases of human 
WNV in 2009.  The drop in the number of diagnosed human cases raises 
several questions.  Have many more individuals been infected than diag-
nosed, and has herd immunity developed? Is the virus losing its virility? 
Have municipal mosquito eradication efforts quelled the ability of the 
primary vector for WNV to infect humans?  The purpose of this study is 
to answer the first question: Is there a high prevalence of immunity to 
WNV due to a large number of individuals with prior exposure to the vi-
rus since 2002?  The hypothesis of the study is that a large portion of the 
population of Fremont County has been exposed to the virus, with most 
humans experiencing few or no symptoms.  And, as a result, immunity to 
the virus is widespread in Fremont County and the rate of disease from 
WNV has dropped due to prevalent immunity in the population 
Materials and Methods 
Serum samples are derived from whole blood samples taken via venipuncture.  Whole blood is spun for 15 minutes in a centrifuge and the se-
rum is separated and frozen for future study.  The sera are then put through an enzyme-linked immunosorbent assay (ELISA).  IgG and IgM 
antibody surveys are then completed on dilute samples of the collected serum.  A microplate reader is used to assess the presence of either IgG 
or IgM antibodies in the serum, determining if the individual providing the sample was or was not previously infected with WNV.  WNV anti-
bodies will adhere to either the WNV IgG antigen (direct) or to the WNV IgM anti-antibody (indirect) adhered to the wells of the ELISA test 
plate.  The microplate reader generates an OD value for each serum sample.  This value is then divided by the OD value of the calibrator to de-
rive an Index Value.  Index Values that are greater than 1.5 indicate a positive presence of WNV antibodies in the serum sample.  Index Values 
lower than 0.8 indicate a negative presence of WNV antibodies in the serum sample. 
Results 
To date, this serosurvey has conducted two different ELISA studies. The second ELISA included four serum samples from 3 individuals with unknown history of WNV infection 
and one individual with diagnosed WNV infection.  The results in the above table are consistent with the expected outcomes: the sample from the previously diagnosed individual 
(subject 4) was positive for the presence of WNV antibodies. 
Future Direction 
At this point in the serosurvey, the methods and materials have been proven to work successfully.  
Additionally, the protocols for conducting the ELISA have been refined and reproduced.  The direc-
tion of this study will now turn to the broader population of Fremont County.  Blood samples from a 
the population will be solicited this summer (2010) for serum separation, storage and study.  We esti-
mate that a minimum of 200 unique samples are needed to adequately study the Fremont County 
population (approximately 35,000).  The study will perform ELISA studies on all samples.  Individu-
als volunteering samples of their blood will answer a questionnaire that will determine if the individ-
ual has been positively diagnosed for WNV, vaccinated against other flaviviruses, and if the individ-
ual has traveled in regions where other flaviviruses are endemic.  Results of this study will help in-
form public policy decisions about continued mosquito eradication efforts and provide data to help 
Wyoming Department of Health better predict the future of WNV human cases. 
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